Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises on Genetron's US$256 million US IPO and Nasdaq listing

  • en
  • zh
  • Language options

23 June 2020

Clifford Chance advises on Genetron's US$256 million US IPO and Nasdaq listing

Leading international law firm Clifford Chance has advised the underwriters led by Credit Suisse and China International Capital Corporation on Genetron Holdings' US$256 million SEC-registered IPO of American Depositary Shares (ADS) and listing on Nasdaq.

Genetron is a leading and fast-growing precision oncology company in China, covering the full cycle on cancer care, from early screening to diagnosis and treatment recommendations and monitoring and continuous care. Genetron offered 16 million ADSs, an upsizing from 13 million, at an offering price of US$16, well above the higher end of the price range (US$13.50). According to Forbes China, this offering is the largest ever precision oncology medicine company IPO.

Partner Fang Liu who led this transaction said, "This is our second SEC-registered offering out of China in a week (following's), highlighting the depth and breadth of our US law capabilities, and our market-leading expertise in the healthcare and biotech sector."

Fang was supported by partners Jonathan Zonis (capital markets), Philip Wagman (tax) and Jefferey LeMaster (regulatory) in New York, and senior associates Yuling Geng and Matt Worden, and associates James Zhang, Tao Yang, Dan Borchert and David G Adams.



泛生子是中国领先且快速成长的癌症精准医疗公司,涵盖从癌症早期筛查、诊断与治疗建议到监测和持续护理的整个癌症治疗全周期。此次ADS的发行规模最后从1,300万股增至 1,600万股,发行单价为16美元,高于定价区间高端13.5美元。据《福布斯中国》报道,这是全球历史上最大规模癌症精准医学公司上市项目(按绿鞋前计)。


纽约办公室合伙人Jonathan Zonis(资本市场)、Philip Wagman(税务)和Jefferey LeMaster(监管)以及包括耿玉玲、Matt Worden、张南、杨弢、Dan Borchert和David G Adams在内的律师团队也为本项目提供支持。